



Europäisches Patentamt  
European Patent Office  
Office européen des brevets



Publication number: **0 629 703 A2**

## EUROPEAN PATENT APPLICATION

Application number: **94202572.7**

Int. Cl.<sup>5</sup> **C12P 21/00, A61K 39 395,  
G01N 33 577, G01N 33 68**

Date of filing: **07.07.87**

This application was filed on 07 - 09 - 1994 as a  
divisional application to the application  
mentioned under INID code 60.

Priority: **07.07.86 US 882181  
01.07.87 US 69412**

Date of publication of application:  
**21.12.94 Bulletin 94/51**

Publication number of the earlier application in  
accordance with Art.76 EPC: **0 255 249**

Designated Contracting States:  
**AT BE CH DE ES FR GB GR IT LI LU NL SE**

Applicant: **MEDAREX, INC.  
12 Commerce Drive  
West Lebanon, NH 03784 (US)**

Inventor: **Fanger, Michael W.  
West View Lane Box 421  
Lebanon,  
New Hampshire 03766 (US)**  
Inventor: **Guyre, Paul M.  
Pinneo Hill Road  
Hanover,  
New Hampshire 03755 (US)**  
Inventor: **Anderson, Clark L.  
406 West Sixth Avenue  
Columbus,  
Ohio 43201 (US)**

Representative: **Harvey, David Gareth et al  
Graham Watt & Co.  
Riverhead  
Sevenoaks  
Kent TN13 2BN (GB)**

**Monoclonal antibodies to Fc receptors for immunoglobulin G on human mono-nuclear phagocytes, bifunctional antibodies, target specific effector cells, targeted macrophages, and immunoassays.**

A human Fc receptor-specific monoclonal antibody is disclosed together with its mode of preparation. Binding of the antibody to Fc receptor is not blocked by human immunoglobulin G. The antibody binds to the high affinity Fc receptor for IgG on human monocytes at a receptor binding site distinct from the ligand binding site for Fc.

A bifunctional antibody or a heteroantibody has an antigen binding region derived from an anti-Fc receptor antibody and an antigen binding region specific for a target epitope or cell; such antibody may target a macrophage when it is bound to surface Fc receptors of the macrophage.

A target-specific effector cell expresses receptor for the Fc portion of IgG, has one antigen binding region derived from an anti-Fc receptor antibody and another specific for a target cell, and the aforesaid bifunctional or hetero-antibody is bound to the Fc receptor of the effector cell; such effector cell can be used in the therapy of cancers, allergies, infectious and autoimmune diseases, and in immunoassays.

The present invention relates to monoclonal antibodies to Fc receptors for immunoglobulin G on human mononuclear phagocytes, bifunctional antibodies, target specific effector cells, targeted macrophages, and immunoassays.

Several types of effector cells have surface receptors that bind the Fc portion of immunoglobulin (IgG). When such cells (monocytes, granulocytes, K cells, etc.) encounter target cells that have been opsonized with IgG antibodies, they form conjugates with the target cells. Subsequently, the effector cells either lyse or phagocytose the target cells, depending upon the effector cell type, the target cell type and the specific Fc receptor type involved.

Two distinct classes of IgG Fc receptors (FcR) have been identified on human monocytes and on the human monocytic cell line U937. Looney, R.J., et al. (1986) *J. Immunol.* 136:1641-1647. One is a 72kDa sialoglycoprotein (p72) with high affinity ( $K_a = 10^8 - 10^9 \text{ M}^{-1}$ ) for monomeric human IgG1 and IgG3 and for murine subclasses IgG2a and IgG3. Alexander, M.D., et al. (1978) *Immunol.* 35:115-123. Anderson, C.L. and Abranham, G.N. (1980) *J. Immunol.* 125:2735-2741. Lubeck, M.D., et al. (1985) *J. Immunol.* 135:1299-1304. The other receptor is a 40kDa molecule (p40) which shows relatively low affinity for monomeric IgG. Looney, et al. *supra*. Jones, D.H., et al. (1985) *J. Immunol.* 135:3348-3353. P40 has been defined by its ability both to form rosettes with erythrocytes coated with murine IgG1 and to bind aggregated murine IgG2b at low ionic strength. In addition, a monoclonal antibody (IV3) has been prepared which binds to the 40kDa receptor and inhibits ligand binding. See Looney, R.J., et al. *supra*. This receptor is present not only on mononuclear phagocytes but on human platelets, neutrophils and eosinophils. Rosenfeld, S.J., et al. (1985) *J. Clin. Invest.* 76:2317-2322.

These two Fc receptors on human monocytes have been shown to mediate anti-T3-induced human T cell mitogenesis by distinct subclasses of murine IgG. The 72kDa FcR mediates murine IgG2a anti-T3-induced stimulation whereas the 40kDa FcR mediates murine IgG1 anti-T3-induced T cell mitogenesis. See Looney, et al. *supra*. Based upon their distinctive affinities for murine IgG subclasses, p72 and p40 are thought to be the human homologues of murine macrophage FcRI and FcRII specific for murine IgG2a and IgG2b 1, respectively. Although not present on monocytes or U937 cells, a third class of IgG FcRs has been described on human neutrophils and null cells.

It has been demonstrated that target cell conjugation and lysis can also be induced by covalently cross-linked heteroantibody made up of both anti-Fc receptor antibody and antibody directed against a target cell epitope. When effector cells bind such heteroaggregates to their Fc receptor, they can specifically bind and lyse target cells which have not been opsonized, but which express the appropriate target antigen. Segal et al. have recently reported cytotoxicity of tumor cells by mouse monocytes with an attached heteroantibody which binds the Fc receptor of the monocyte on one end and with tumor cell epitopes on the other end. The targeting of effector cells with conventional heteroantibodies, however, is likely to be only marginally effective *in vivo* because the binding of antibody to Fc receptors can be blocked by physiological concentrations of IgG.

#### Disclosure of the Invention

This invention pertains to monoclonal antibodies which are specific for the human high affinity Fc receptor of IgG, the P72 receptor, and which bind to the Fc receptor without being blocked by human IgG. The antibodies bind specifically through their antigen combining region and independent of their Fc portion, to human receptor for the Fc portion of IgG. The antibodies bind to a site on the Fc receptor distinct from the binding site for the Fc region of IgG (ligand) and the antibodies are capable of binding a ligand-occupied receptor.

The anti-Fc receptor antibody of this invention can be made by monoclonal antibody producing techniques. Fc receptor protein can be obtained for immunization by preparing a cell fraction containing Fc receptor from a cell line that expresses Fc receptor (e.g. the U937 line, a human monocytic cell line that expresses Fc receptor for human IgG). The cells can be pretreated in culture with IFN-gamma to enhance the yield of Fc receptor protein. Fc receptor protein is purified by affinity purification from cell lysates. An animal is immunized with the purified receptor protein and antibody-producing cells are harvested from the animal and fused with a myeloma cell or other immortalizing cell to produce hybridomas. The hybridomas are cloned and clones are selected for production of antibody to Fc receptor which is not blocked by human IgG.

The selection of antibody which binds to the Fc receptor through its antigen binding region (distinct from the Fc portion of the antibody) is complicated by the fact that the Fc portion of IgG of the animal species may bind human Fc receptor. For example, two of the four murine IgG subclasses - IgG2a and IgG3 - bind to the high affinity human Fc receptor via their Fc portion. In such instances selection for an

facilitated as follows. After initial screening of hybridomas for production of Ig which binds the receptor, hybridomas which produce antibody of the subclass which is bound via its Fc region by the human Fc receptor, are eliminated from consideration. The remaining hybridomas are evaluated for production of antibody which binds Fc receptor independently of their Fc portion.

5 The anti-Fc receptor antibody of this invention can be used to produce target-specific effector cells for treatment of cancer, allergies, and infectious and autoimmune diseases. Antibody specific for a target cell (targeting antibody) can be linked to the Fc receptor of effector cell through the Fc-specific antibody of this invention. The linkage mediated by this anti-Fc receptor antibody is not disruptable by IgG because binding to the receptor does not involve the Fc portion of the antibody.

10 For the purpose of targeting effector cells, a bifunctional antibody (used herein to mean a single antibody or antibody fragment with a dual binding specificity) or a heteroantibody (used herein to mean an aggregate of two or more antibodies (or antibody fragments) each antibody having a different specificity) can be produced. In general, the bifunctional antibody or heteroantibody comprises:

- a. at least one antigen binding region derived from an anti-Fc receptor antibody whose binding to human
- 15 Fc receptor is not blocked by human immunoglobulin G; and
- b. at least one antigen binding region specific for a target cell.

The binding of bifunctional or heteroantibody to the effector cell results in a targeted effector cell i.e., an effector cell with attached bifunctional or heteroantibody containing antigen binding regions which are specific for a desired target cell. The targeted effector cells can be used to bring about antibody dependent

20 cell mediated cytotoxicity (ADCC) of the target cells in vivo.  
The target cell can be a cancer cell or other cell whose elimination would be beneficial to the host, for example, an auto-antibody producing cell found in autoimmune diseases, or an IgE producing cell found in allergies. The target cell specificity of the bifunctional antibody or the heteroantibody is derived from a targeting antibody i.e., an antibody specific for a target cell-associated or target cell-specific antigen. The

25 use of the Fc specific antibody of this invention provides for attachment of the targeting antibody to monocyte effector cells by a linkage which is not disrupted by physiological levels of immunoglobulin G encountered in vivo. Thus, the targeted effector cells can be given in vivo without loss of effector cell specificity due to IgG competition for Fc receptor sites.  
The anti-FcRI antibody of this invention has other therapeutic applications as well as several diagnostic

30 applications. The antibody can be used as a targeting antibody to target FcRI-bearing cells. The antibody can also be used to induce capping and removal of Fc receptors on monocyte or other cells. Diagnostic applications of the antibodies include their use in assays for FcRI receptor levels and assays for substances that influence FcRI receptor levels.

The invention will now be described in more detail in the following description, which is given by way of

35 example only, and which is to be read in conjunction with the accompanying drawings, in which:

Figure 1 shows SDS-PAGE of affinity adsorbed lysates of surface radiiodinated U937 cells.

Figure 2 shows SDS-PAGE analysis of affinity adsorption with ligand or with mab 32 after preclearing U937 lysates with ligand or with mab 32.

Figure 3 shows the results of isoelectric focussing of p72 purified either with ligand or with mab 32.

40 Figure 4 shows that human IgG does not interfere with the binding of Mab 32 to U937 cells, but blocks, almost completely, the binding of the mouse IgG2a myeloma UPC-10.

Figure 4b shows that human IgG does not interfere with the binding of Mab 32, 22, 44, 62 and 197 to U937 cells, but blocks almost completely the binding of mouse IgG2a UPC-10; and the increased binding of Mab 32, 22, 44, 62 and 197 to IFN-gamma treated U937 cells.

45 Figure 5 shows the fluorescence intensity of cells stained with mab 32.

Figure 6 shows the cytotoxicity of chicken red blood cells (cRBC) by IFN-gamma treated U937 cells mediated by the heteroantibody Mab32 x Fab anti-cRBC.

Figure 7 shows cytotoxicity of cRBC by interferon-gamma treated and untreated U937 cells.

50 Figure 8 shows cytotoxicity of chicken cRBC by interferon-gamma treated and untreated human peripheral blood monocytes.

Figure 9 shows the cytotoxicity of cRBC by IFN-gamma treated U937 cells in the presence of the heteroantibody Mab 32 x Fab anti-cRBC and human IgG1.

Figure 10 shows cytotoxicity of cRBC by IFN-gamma treated and untreated human peripheral blood monocytes in the presence of the heteroantibody Mab 32 x Fab anti-cRBC and human IgG1.

Detailed Description of the Invention

The antibody of this invention binds the high affinity (p72) Fc receptor (FcRI) for human IgG without being blocked by human IgG. Preferred anti-FcRI receptor antibody has the following characteristics:

- a. the antibody reacts specifically with the high affinity Fc receptor
- b. the antibody reacts with the receptor through its antigen combining region independent of its Fc portion
- c. the antibody reacts with an epitope of FcRI which is distinct from the Fc (or ligand binding) site of the receptor, and
- d. the antibody binds ligand (Fc) occupied receptor.

The monoclonal anti-Fc receptor antibody of this invention can be produced by conventional monoclonal antibody methodology e.g., the standard somatic cell hybridization technique of Kohler and Milstein, *Nature* 256: 495 (1975). Although somatic cell hybridization procedures are preferred, in principle, other techniques for producing monoclonal antibody can be employed e.g., viral or oncogenic transformation of B lymphocytes.

Fc receptor for immunization of an animal can be prepared from lysates of human cells which express the receptor. A preferred receptor-bearing cell line is the human monocytic cell line U937; however, other monocytic cells such as HL-60 cells or freshly isolated monocytes can be used. Because interferon-gamma enhances Fc receptor expression, the cells can be cultured in the presence of interferon-gamma (e.g., 100 IU/ml) before receptor preparation to enhance the yield of receptor protein.

A partially purified preparation of the receptor can be made by lysing receptor-bearing cells and then purifying the receptor by immunoadsorbent chromatography. Cells can be lysed in a buffer containing a detergent such as NP40. The immunoadsorbent can be prepared by attaching human IgG to a water-insoluble material such as an activated Sepharose™ resin. The Sepharose resin with attached human IgG is poured into a column. The cell lysate is passed through the column under conditions which permit adsorption of the cellular Fc receptor protein by the IgG coupled to the resin. The adsorbed Fc receptor protein can be eluted with a mildly acidic elution buffer. The purified receptor can then be used for immunization of an animal to produce anti-receptor monoclonal antibody.

As an alternative to the use of partially purified receptor protein, whole FcRI-bearing cells can be used as immunogen. For example, whole interferon-gamma treated U937 cells can be used to elicit anti-FcRI antibody.

The preferred animal system for preparing hybridomas is the murine system. Hybridoma production in the mouse is a very well-established procedure. Immunization protocols and techniques for isolation of immunized splenocytes for fusion are well known in the art. Fusion partners (e.g., murine myeloma cells) and fusion procedures are also well-known.

Selection of murine hybridomas producing antibody against the FcRI for IgG of human monocytes, however, is complicated by the fact that two subclasses of murine IgG - the IgG2a and IgG3 subclasses - are ligands capable of binding with high affinity to this receptor. Thus, assays for monoclonal antibody capable of binding to the receptor would register as positive all murine antibodies of these two subclasses. This obstacle can be avoided by first screening hybrid cells for production of antibody reactive with the cell line which was the source of Fc receptor, then eliminating hybrid cells which produce IgG2a and IgG3 antibodies and finally evaluating remaining hybridomas for production of antibody against high affinity receptor. This strategy is further detailed in the exemplification below.

Employing the methodology described, five murine monoclonal anti-FcRI antibodies were prepared. The antibodies are designated mab 22, mab 32, mab 44, mab 62 and mab 197. Each of the antibodies exhibit the preferred characteristics set forth above.

The anti-Fc receptor antibody of this invention can be used to produce target-specific effector cells, i.e., effector cells which are capable of recognizing and binding to a target cell and exerting their effector function. It provides a means for attaching to an effector cell an antibody or antibody-binding fragment directed against a target cell. The attachment is not disruptable by physiological concentrations of IgG because the anti-Fc antibody which mediates the attachment binds the receptor through its antigen-binding region. Effector cells, such as macrophages, targeted in this way can be employed to bring about antibody-dependent cell-mediated killing of target cells.

To target effector cells, bifunctional antibodies or heteroantibodies are employed. These antibodies have dual antigen binding specificity - one specificity for the Fc receptor (preferably the high affinity Fc receptor) and one specificity for an epitope of the target cell. The Fc receptor specificity mediates linkage to the effector cell through a known cytotoxic trigger molecule. The target cell specificity provides for recognition and binding to the target cell.

Bifunctional antibodies are single, divalent antibodies which have two different antigen binding sites. Bifunctional antibodies for targeting have one binding site for Fc receptor and one binding site for a target cell epitope.

Heteroantibodies are two or more antibodies or antibody binding fragments (Fab) linked together, each antibody or fragment having a different specificity. Heteroantibodies for targeting comprise an antibody (or antigen binding fragment specific for Fc receptor, coupled to an antibody (or antigen binding fragment thereof) specific for a target cell epitope.

Bifunctional antibodies can be produced by chemical techniques (see e.g., D. M. Kranz et al., *Proc. Natl. Acad. Sci. USA* 78:5807 (1981)) by "polydome" techniques (See U.S. Patent 4,474,893, to Reading) or by recombinant DNA techniques. Heteroantibodies can be prepared by conjugating Fc receptor antibody with antibody specific for an epitope of a target cell. A variety of coupling or crosslinking agents can be used to conjugate the antibodies. Examples are protein A, carbodiimide, and N-succinimidyl-3-(2-pyridyl-dithio) propionate (SPDP). SPDP is the preferred agent; procedures for crosslinking antibodies with this agent are known in the art. See e.g., Karpovsky et al., (1984) *J. Exp. Med.* 160:1686; Liu, M.A. et al., (1985) *Proc. Natl. Acad. Sci. USA* 82:8648.

Target cells are cells whose elimination would be beneficial to the host. One important type of cell is a tumor cell. Effector cells can be targeted with bifunctional or heteroantibody having specificity for FcRI and specificity for a tumor associated or tumor specific antigen.

Antibodies with a desired tumor specificity for production of bifunctional antibody or heteroantibody can be produced or can be selected from available sources. Monoclonal antibodies against tumor-associated antigens can be made by the methods of Koprowski et al., U.S. Patent 4,172,124. Many suitable anti-cancer antibodies are presently available.

Specific anti-tumor antibodies would include, but not be limited to:

Antibody	Specificity
AML-2-23, PM-81, PMN-6, PMN-19	Myeloid Leukemia
SCCL-1, SCCL-175	Small Cell Carcinoma of the Lung
OC1-25, OVCT-3	Ovarian Carcinoma
COL-1, COL-2, COL-3, ... COL-13	Colon Carcinoma

In addition to tumor cells, the effector cell can be targeted against auto-antibody producing lymphocyte for treatment of autoimmune disease or an IgE-producing lymphocyte for treatment of allergy. The target can also be microorganism (bacterium or virus) or a soluble antigen (such as rheumatoid factor or other auto-antibodies).

Effector cells for targeting are human leukocytes, preferably macrophages. Other cells would include monocytes, IFN-gamma activated neutrophils, and possibly IFN-gamma activated natural killer (NK) cells and eosinophils. Macrophages can be treated with IFN-gamma before targeting, to increase the number of Fc receptors for attachment of the targeting antibody or heteroantibody. The effector cells may also be activated before targeting by other cytokines such as tumor necrosis factor, lymphotoxin, colony stimulating factor, and interleukin-2. If desired, effector cells for targeting can be obtained from the host to be treated.

The targeted effector cells can be administered as a suspension of cells in a physiologically acceptable solution. The number of cells administered can be in the order of  $10^2$ - $10^9$  but will vary depending on the therapeutic purpose. In general, the amount will be sufficient to obtain localization at the target cell and to effect target cell killing by antibody dependent mediated cytotoxicity (ADCC). Routes of administration can also vary. In tumor therapy, for instance, depending upon the localization of a tumor, the targeted effector cells could be administered intravenously, or directly into tumor sites; as for example, directly into the peritoneal cavity in the case of ovarian carcinoma.

Therapy with targeted effector cells can be performed in conjunction with other techniques for removal of targeted cells. For example, anti-tumor therapy with effector cells armed with FcRI anti-tumor antibody can be used in conjunction with surgery, chemotherapy or radiotherapy. Additionally, combination immunotherapy may be used to direct two distinct cytotoxic effector populations toward tumor cell rejection. For example, anti-tumor antibodies linked to anti-T3 that will trigger cytolytic T lymphocytes to lyse tumor cells may be used in conjunction with anti-FcRI antitumor heteroantibodies. Protocols based on these concepts may be especially effective in removing residual tumor cells in patients induced into remission by chemotherapy and irradiation.

The anti-Fc receptor antibody of this invention has additional utility in therapy and diagnosis. The Fc

antibody can be used to target lipid vesicles containing anticancer drugs for treatment of certain hematological cancers (e.g. acute myeloid leukemia) or to target lipid vesicles containing factors (such as gamma-IFN) which activate monocytes. The antibody, if of the appropriate murine IgG subclass (e.g. IgG2a) can be used directly *in vivo* to eliminate Fc receptor bearing cells (e.g. myeloid leukemia cells) via natural complement or ADCC mechanisms.

The antibody can be employed to modulate Fc receptor levels on monocytic cells. For example, in autoimmune diseases (such as rheumatoid arthritis) the antibody can be administered in a form that induces "capping" and elimination of Fc receptors on the cell surface. The reduction of Fc receptors can interfere with monocyte clearance of antibody coated self-cells in patients. Mixtures of anti-Fc receptors can also be used for this purpose.

Diagnostic applications of the anti-FcRI antibody of the invention can be based on the use of the antibody to quantify the distribution or number of Fc receptors on cells. The antibody can be employed in assays for agents which influence receptor expression (e.g. interferon-gamma which enhances Fc receptor expression). For example, in an assay for interferon-gamma the anti-FcRI antibody labeled (radioisotopically, enzymatically or fluorescently) can be used to quantify FcRI levels on cells exposed to a test sample. Receptor levels will be related to the amount of interferon-gamma in the sample.

The antibody can also be used to subclassify patients with rheumatologic disorders which are related to Fc receptor levels or to the ability of a patient's cells to respond to interferon by enhanced expansion of Fc receptors.

Based on the increased expression of FcRI on IFN-gamma plus dexamethasone-treated monocytes it is anticipated that anti-FcRI monoclonal antibodies will be excellent markers of inflammatory macrophages. It is possible that the accumulation and activation of mononuclear phagocytes at sites of inflammation (including but not limited to infectious foci, septic arthritis, atherosclerotic plaques) can be detected by radio-imaging using radiolabelled antibodies to the FcRI on such cells.

The invention is illustrated further by the following non-limitative exemplification:

#### Exemplification

#### Materials and Methods

#### Chemical and Reagents

Cytochrome c Type VI, superoxide dismutase, pepstatin, chymostatin, leupeptin, antipain, rabbit muscle actin and phenylmethylsulfonylfluoride (PMSF) were purchased from Sigma Chemical Co., St. Louis, MO; Dextran T500, Ficol-Hypaque, Sepharose 4B, CNBr-activated Sepharose, Protein A-Sepharose CL-4B from Pharmacia Fine Chemicals, Piscataway, NJ; tetanus toxin, octyl- $\beta$ -D-glucopyranoside (octylglucoside) and papain from Calbiochem, La Jolla, CA; human anti-tetanus toxin antibody (HyperTet™) from Cutter Laboratories, Berkeley, CA; chloroglycouril from Pierce Chemical Co., Rockford, IL; carrier-free  $^{125}$ I- (IMS 300) from Amersham, Arlington Heights, IL; cytochalasin B from Aldrich Chemical Co., Milwaukee, WI; goat F(ab')<sub>2</sub> antimurine Ig (anti-mIg), both fluorescein isothiocyanate-conjugated (FITC) and unconjugated, from Cappel, West Chester, PA, unless indicated otherwise; RPMI 1640 from Gibco, Grand Island, NY, and from K.C. Biologicals, Lenexa, KS; Fetal bovine serum (FBS) from Sterile Systems, Logan, UT, and a mixture of low molecular weight markers from Biorad, Richmond, CA. Recombinant gamma interferon was kindly donated by Genentech, South San Francisco, CA. 1,25-dihydroxycholecalciferol (1,25(OH)<sub>2</sub>D<sub>3</sub>) was a gift from Hoffman LaRoche, Nutley, NJ. Other chemicals were of analytical grade and were obtained commercially.

NP40 lysis buffer contained 1% NP40, 110mM NaCl, 10mM EDTA, 2mM PMSF, 10ug/ml pepstatin, 10ug/ml chymostatin, 10ug/ml leupeptin and 10ug/ml antipain in 20 mM Tris buffer, pH 7.1. Krebs Ringer phosphate buffer with glucose (KRPglu) consisted of 135mM NaCl, 5mM KCl, 1.2mM MgSO<sub>4</sub>, 1mM CaCl<sub>2</sub>, 4.3mM glucose in 10mM sodium phosphate buffer, pH 7.4. Phosphate buffered saline (PBS) was 145mM NaCl in 20mM phosphate buffer, pH 7.0. PBS-k contained 130mM NaCl and 5mM KCl in 10mM phosphate buffer, pH 7.4.

#### Antibodies

The monoclonal antibody against the high affinity FcR (herein designated mAb 32 and when subcloned, 32.2), was prepared as follows. A partially purified detergent lysate of the high affinity FcR from U937 cells was obtained in a manner similar to a published method (See Anderson, C.K., et al., (1984) J. Immunol.

134:465-470). U937 cells were lysed in 1% NP40 and the lysate was allowed to incubate with Sepharose mlgG for 8 hours. The adsorbent was washed thoroughly and was eluted with 0.5M acetic acid in 30mM octylglucoside. The eluate was promptly neutralized with 2M Tris and the amount of protein eluted was determined by a Folin assay (Peterson, G.L. (1977) *Anal. Biochem.* 85: 346-356). The tubes containing the bulk of the protein were pooled, concentrated by vacuum dialysis using an Amicon YM-10 filter and a Minicon apparatus to 0.5ml and emulsified with an equal volume of Freund's adjuvant, either complete for the first injection or incomplete for subsequent ones. A mouse was immunized intraperitoneally 4 times at roughly 4 week intervals, the last 2 immunizations using antigen derived from U937 cells cultured 72 hours in IFN-gamma, 100 IRU/ml, to increase the yield of FcR (Guyre, P.M., et al. (1983) *J. Clin. Invest.* 72:393-397). Five days following the last immunization the splenocytes were fused with cells of the NS1 myeloma line by standard techniques (Kohler, G. and Milstein, C. (1975) *Nature*, 256:495. Ball, E.D., et al., (1982) *PNAS* 79:5374-5378). Supernatants of the hybrids were screened for their ability to bind to U937 cells by an indirect immunofluorescence assay using a flow cytometer. Chosen hybrids were cloned by limiting dilution, rescreened and expanded either in culture or in ascites fluid. The protein from clone mab 32 was found to be an IgG1 antibody by an immunoblot assay using isotype-specific antisera. IgG of this clone was precipitated from ascites by making the solution 40% in ammonium sulfate. The precipitate was redissolved and dialyzed against 20mM Tris buffer, pH 8.6. High performance ion exchange chromatography (HPLC) was carried out on a semi-preparative PROTEIN-PAK-5PW (Waters, Milford, MA) column. The initial eluting buffer was 20mM Tris, pH 8.6 delivered by pump A. 20mM Tris, 0.3M NaCl, pH 8.6 was delivered by pump B. A sixty minute linear gradient, 0-100% B, at a flow rate of 8 ml/min was used for elution. The main peak corresponding to IgG was pooled. For some experiments the purified IgG was passed over a Sepharose Protein A column to remove traces of IgG2a to less than 0.005%. Pepsin digestion of whole antibody was performed essentially as described by Parham (See Parham, P. (1983) *J. Immunol.* 131: 2895-2902) except that the digestion time was 3 hr and the pH 3.6. F(ab')<sub>2</sub> was purified by high performance gel filtration chromatography using a TSK 250 column (Biorad). Fab' was made from F(ab')<sub>2</sub> by reducing with 1mM dithiothreitol for 1 hr at room temperature and alkylating with an excess of iodoacetamide. The Fab' was purified by HPLC using the TSK 250 column.

The preparation of mab 22, mab 44, mab 62 and mab 197 were as above, except that for mabs 22, 44 and 197 the immunogen was IFN-gamma- and dexamethasone activated U937 cells. All procedures and preparations were the same as for mab 32.

The preparation and properties of monoclonal IV3 have been described. See e.g. Looney, R.J. et al. (1986) *J. Immunol.* 136:1641-1647. IV3 was used as supernatant fluid from the culture of cloned cells. Fab fragments of IV3 were prepared as described Looney, R. J. et al. IgG or IgM fractions of murine monoclonal antibodies or myeloma proteins MOPC 141 (IgG2b), anti-Vk3b (IgG2b), P3 (IgG1), AML-2-23 (IgG2b), MY23 (IgG1), RPC5 (IgG2a) and MMA (IgM) were purified from ascites fluids by ion exchange chromatography unless otherwise indicated. In some cases, the supernatant fluid of cloned hybridoma cells was used. Gap8.3 ascites fluid was donated by Dr. Christopher Frantz, Department of Pediatrics, University of Rochester. MY7 was purchased from Coulter, Hialeah, FL. Leu-M3, an anti-monocyte monoclonal antibody, was obtained from Becton-Dickinson, Mountain View, CA.

Immune complexes containing human IgG were prepared by incubating tetanus toxin (200Lf/ml) with Hyper-Tet™ antibody (200Lf/ml) for 1 hr at 37°C. Insoluble complexes were pelleted by centrifugation at 13,000 x g for 1 min, washed once with PBS-K, and resuspended in the original volume of PBS-K. Protein concentration was determined by adding 0.1 M NaOH and measuring absorbance at 280 nm, assuming an extinction coefficient (1%) of 14. Pooled human IgG purified by ion exchange chromatography was covalently linked to Sepharose 4B by a modification of the cyanogen bromide technique (March, S.C. et al., (1974) *Analyt. Biochem.* 60:149-152) at a ratio of 7.6mg IgG/ml Sepharose. Anti-mlg was linked to CNBr-activated Sepharose according to the manufacturer's instructions at a ratio of 1mg protein/ml Sepharose. Prior to use the Sepharose adsorbents were washed x4 with 1% NP40 in PBS containing 5mM KI.

#### 50 Cells

Human granulocytes were obtained from the peripheral blood of normal donors by separation from mononuclear cells on Ficoll-Hypaque, sedimentation of erythrocytes using 3% dextran in PBS and finally hypotonic lysis of residual erythrocytes. Preparations were 98% granulocytes. Nonnuclear cells were obtained by Ficoll-Hypaque separation (Boyum, A. (1968) *Scand. J. Clin. Lab. Invest.* 21:77-83 (Supple. 77)). Cells of the U937, HL60, K562, Daudi, Raji, Molt4, Jurkat and J774 lines were maintained in continuous culture as described. Many of the cell lines used were obtained from the American Type Culture Collection. All cells were washed x3 in PBS prior to use and were 95% viable when tested by trypan blue exclusion.

### Radiolabeling and Affinity Adsorption

Cells were surface radiolabeled by the chloroglycouril method (Fraker, P. J. and Speck, J. C. (1978) *Biochem. Biophys. Research Comm.* 80:849-857).  $0.7 \times 10^6$  cells in PBS at  $1.43 \times 10^6$  ml were incubated with 1 mCi  $^{125}$ I for 30 min at  $0^\circ\text{C}$  in a scintillation vial coated with 5  $\mu\text{g}$  chloroglycouril. The reaction was quenched and the cells were washed x3 with 5 mM KI in PBS. The cells were then lysed in NP40 lysis buffer for 30 min at  $0^\circ\text{C}$ . Cell nuclei and other insoluble material were pelleted by centrifugation at  $7800 \times g$  for 20 min.

### SDS-PAGE and Isoelectric Focussing

Sepharose-anti-mIg (25ul) was sensitized with monoclonal antibodies by incubating for 3 hrs at  $4^\circ\text{C}$  with 100ul supernatant fluid or Ig purified from ascites fluid (10ug/ml) and the unbound material washed away x4 with 0.75ml BSA PBS. Portions of labeled cell lysate (50ul) were incubated for 2 to 12 hr at  $0^\circ\text{C}$  with 25ul antibody-sensitized Sepharose-anti-mIg. Separate 50ul portions of lysate were incubated with 25ul Sepharose-hIgG. The Sepharose conjugates were washed x7 with 0.75ml 1% NP40 PBS KI and in preparation for sizing gel electrophoresis were incubated for 2 min in a boiling water bath with 80ul Laemmli sample buffer containing 20mM dithiothreitol instead of 2-mercaptoethanol. The supernatant was acetylated by adding 5ul 1M iodoacetamide and was analyzed by SDS-PAGE and autoradiography as described (Anderson, C. L. (1982) *J. Exp. Med.* 156:1794-1805). The molecular weight markers included in all gels were  $^{125}$ I-bovine serum albumin,  $^{125}$ I-rabbit muscle actin, phosphorylase B, ovalbumin, carbonic anhydrase, soybean trypsin inhibitor, and lysozyme. For isoelectric focussing, the washed adsorbants were incubated for 15 min with 80ul of the urea-containing O'Farrell sample buffer and the eluates were electrophoresed on a vertical slab gel prepared as described for the first dimension of the O'Farrell procedure. See O'Farrell, P. H. (1975) *J. Biol. Chem.* 250:4007-4021. The pH gradient was determined by cutting the lateral lanes of the gel into 1cm sections and incubating each section overnight in 1ml  $\text{H}_2\text{O}$ . The gels were stained and dried, and autoradiographs were prepared using prelogged x-ray film and enhancers at  $-70^\circ\text{C}$  as described. See Anderson, C. L. *Supra*. Densitometric tracings of the p72 band appearing on autoradiographs were enlarged 157% using a photocopier and were cut out with scissors and weighed.

### Binding and Inhibition Experiments

A human IgG1 myeloma protein (Arr) and the IgG fraction of mab 32 were radiolabeled by the chloroglycouril method to a specific activity of 1-5uCi/ug. Preliminary experiments established that equilibrium and saturation were achieved with  $4 \times 10^6$  U937 cells/ml after 2hr at  $0^\circ\text{C}$  at 0.3 ug/ml for mab 32 and 1.5ug/ml for hIgG1. Inhibition of the binding of both  $^{125}$ I-hIgG and  $^{125}$ I-mab 32 to U937 cells by unlabeled preparations of both hIgG1 and mab 32 was evaluated by incubating the radioligand or radioantibody with cells in the presence of titrated amounts of unlabeled antibody or ligand under the above conditions. Cell-bound radioactivity was separated from free by centrifuging triplicate 50ul portions of the cells suspension through an oil mixture as described. Anderson, C. L. and Abraham, G. N. (1980) *J. Immunol.* 125:2735-2741. Nonspecific binding was measured in replicate samples containing a great excess of ligand (3mg/ml) or antibody (333ug/ml). Percent inhibition was calculated as described. Anderson, C. L. and Sciegelberg, H. L. (1981) *J. Immunol.* 126:2470-2473.

### Fluorescence and Flow Cytometry

One million cells were incubated for 2 hr at  $4^\circ\text{C}$  in 50ul of antibody (either mab 32 or IV3 supernatant or 10ug/ml solutions of purified IgG fractions of ascites fluid) diluted in RPMI 1640 growth medium containing 4mg/ml hIgG to block nonspecific binding. The cells were washed x3 in PBS containing 0.1% NaN<sub>3</sub>, were resuspended and incubated for 2 hr at  $4^\circ\text{C}$  in 50ul FITC anti-mIgG (TAGO, Burlingame, CA, or Boehringer-Mannheim, Indianapolis, IN) and were washed a final 3 times. Stained cells were analyzed on an Ortho 50H Cytofluorograf flow cytometer using argon lasers at 300mW or 500mW power. Green fluorescence was collected through a 525 nm bandpass filter on 10,000-50,000 cells gated for low angle light scatter (to exclude erythrocytes, platelets, dead cells and debris) and  $90^\circ\text{C}$  light scatter (to distinguish monocytes or neutrophils from lymphocytes). See Salzman, G. C. et al. (1975) *Acta Cytol.* 19:374. The  $90^\circ\text{C}$  light scatter signal characteristic of monocytes was determined by separately staining an aliquot with anti-monocyte antibody Leu-M3. Based on these data, gates for  $90^\circ\text{C}$  light scatter were adjusted so that the green fluorescence signal of monocytes and lymphocytes in mononuclear cell suspensions could be



separately collected. Green fluorescence was collected as a linear signal.

## Results

5 The strategy for the development of monoclonal antibodies against the high affinity 72kDa FcR had to deal with the observation that two of the four murine IgG subclasses, IgG2a and IgG3, bound with high affinity to this FcR. Thus, any assay for FcR binding would register all antibodies of these two subclasses. Our protocol, therefore, called for immunizing a mouse with partially purified FcR from U937 cells, screening the hybrid supernatants for an Ig capable of binding U937 cells, eliminating from further  
10 consideration IgG2a and IgG3 antibodies, and evaluating the remaining antibodies for their capacity to immunoprecipitate 72kDa surface molecules. (Additional monoclonal antibodies of this specificity (designated mab 22, mab 44 and mab 197) were prepared using whole U937 cells.)

Twenty-nine supernatants from the partially purified FcR immunization contained Ig capable of binding U937 cells. Of these, 12 were of the IgG2a subclass, 1 was IgG3, 7 were IgG1, 2 were IgM, and 7 were  
15 either of mixed subclass or could not be typed. The supernatants of the cultures of cloned cells were then evaluated for their ability to bind to a 72kDa cell surface molecule by an affinity adsorption assay.

Detergent lysates of U937 cells radioiodinated by the chloroglycyl method were incubated, (shown in Figure 1) from left to right, with Sepharose-anti-mIg sensitized with purified murine IgG2a myeloma protein RPC5 (lane 1) or with mab 32 (lane 3); with Sepharose-human IgG (lane 4); or with Sepharose-anti-mIg  
20 sensitized with mab IV3 (lane 5). The three samples analyzed in the right hand panel were eluted from Sepharose-anti-mIg sensitized with either intact IgG of mab 32 (lane 6), with Fab fragments of pooled human IgG (lane 7), or with Fab' fragments of mab 32 (lane 8). The immunoadsorbents were washed free of unbound radioactivity and the bound material was eluted in an SDS-containing sample buffer and analyzed by electrophoresis on an SDS-polyacrylamide gel followed by autoradiography. Adjacent lanes not shown  
25 but marked on the lateral margins of the autoradiograph contained radioiodinated bovine albumin (68kDa) and rabbit muscle actin (43kDa). Lane 2 contains a mab of the IgG2a subclass.

"final adsorbants". The eluates from the washed set of final adsorbants were processed as described for Figure 1. A photograph of the set of 72kDa bands, the only bands appearing on the autoradiograph, is displayed vertically. Densitometric tracings on paper of the autoradiograph bands were cut out and weighed; band density is expressed as mg per band. Percent depletion of p72 by the precipitating adsorbant was calculated by comparing lanes 2 and 3, 1 and 4, 2 and 5, and 1 and 6.

Comparing lanes 1 and 4 of Figure 2, mab 32 precleared 73% of the p72 subsequently purified by mlgG2a. The reciprocal experiment, preclearing with mlgG2a and then purifying p72 with mab 32, indicates that 89% of p72 was precleared with mlgG2a (lane 3) compared with the mlgG1 sham control (lane 2). Control experiments were performed in which the same reagent (mab or ligand) was used both for preclearing and for subsequent purification. These showed the efficiency of preclearing to range from 81% when mab 32 was used (lanes 2 and 5) to 93% when mlgG2a was used (lanes 1 and 6). We conclude, therefore, that mab 32 binds to the same high affinity 72kDa FcR purified by ligand affinity adsorption.

The third method used to test whether the ligand and mab 32 bind the same 72kDa molecule was isoelectric focusing. Figure 3 shows the results.

A detergent lysate of radiolabeled U937 cells was incubated with Sepharose-anti-mlg sensitized with either murine IgG2a myeloma RPC5 (lane 1) or mab 32 (lane 3); with Sepharose-human IgG (lane 4) or with Sepharose-anti-mlg sensitized with mab IV3 (lane 5). The radioactivity bound to the washed immunoadsorbants was eluted with urea-containing sample buffer and was analyzed by isoelectric focusing and autoradiography. The pH gradient is shown in the left margin. Lane 2 analyzed a mab still under investigation.

An identical pattern of ten distinct bands having isoelectric points ranging from pH 5 to pH 7 was seen in both lanes (Figure 3, lanes 1 and 3). A similar although subtly distinct pattern of bands was seen in lane 5 analyzing the eluate from the IV3 affinity adsorbent which purified only the 40kDa FcR. The eluate from Sepharose-human IgG which purifies both the 72 and 40 kDa molecules appears in lane 4 as a composite of the two isoelectric focusing patterns with some of the p72 molecules appearing dimmer than in lanes 1-3, most likely because the p72-ligand bond resists dissociation by urea unlike the p40-ligand bond and unlike antibody-antigen interactions (lanes 1-3). Thus, these data further substantiate the identity of the 72kDa molecules purified by both FcR ligands and mab 32.

We further quantified the ability of both mab 32 and a ligand. In this case a human IgG1 (hIgG1) myeloma protein (Arr), to inhibit the binding to U937 cells of either  $^{125}$ I-human IgG1 (Arr) or  $^{125}$ I-mab 32. Figure 4 shows the results of these inhibition experiments. Under conditions of saturation and equilibrium, U937 cells were incubated at 4°C with  $^{125}$ I-mouse myeloma IgG2a (UPC 10) or  $^{125}$ I-mab 32 in the presence of varying amounts of unlabeled human IgG1. Bound labeled antibody was separated from free by centrifuging the cells through oil and was quantified by counting the radioactivity associated with the cell pellets. Nonspecific binding measured in the presence of a great excess (100 fold) of unlabeled antibody was subtracted from total binding to give specific binding. Percent inhibition, calculated as described in Materials and Methods, was plotted versus the concentration of inhibitor protein. Nonspecific binding was 6-8% of total binding.

As seen in figure 4, human IgG at concentrations found in human serum (10-15 mg/ml) does not inhibit the binding of mab 32 to Fc receptors on U937 cells. On the other hand, if a ligand which binds to the Fc receptor through the ligand's Fc region is used, serum levels of IgG inhibit the binding by more than 95%. In figure 4, the mouse myeloma IgG 2a designated UPC-10 was used as the ligand. Identical inhibition by human IgG has also been demonstrated in experiments using human IgG1 as the ligand. We conclude that the binding of mab 32 to cells does not interfere with ligand binding to the FcR binding site and that ligand binding does not inhibit mab 32 binding.

The types of cells which bear the epitope recognized by mab 32 were evaluated by indirect immunofluorescence and flow cytometry and data are presented in Table 2. It is apparent that mab 32 binds to those cells which are known to bear the high affinity IgG FcR, namely U937, HL60, and monocytes. Lymphocytes were negative as were the B cell lines Raji and Daudi, and the T cell lines Molt4 and Jurkat. Some samples of neutrophils showed low level binding of mab 32. Figure 5 shows the fluorescence intensity of cells stained with mab 32. Each panel displays histograms of fluorescence intensity vs cell number for cells stained with mab 32 (shaded area) and murine monoclonal IgG2b control (solid line). Cells shown are: a) lymphocytes, b) monocytes, and c) U937 cells. Monocytes and lymphocytes from a single suspension of blood mononuclear cells were identified by gating on forward and 90° light scatter. Panels a and b are 64 channel histograms (20,000 cells counted). The fluorescence detection gain was set at 1500 to bring the lymphocytes on scale. Panel c is a 256 channel histogram gated on forward angle light scatter (11,000 cells counted). The fluorescence detection gain was set at 140

Table 2

Cell Type	Staining Intensity of Mab32 on Various Cell Types			
	Mab32	Control	Mean Fluorescence Intensity	
U937	103±48	26±10	n	n
HL60	78±18	16±7	11	6
Monocytes	113±37	29±11	7	3
Lymphocytes	10±2	9±3	8	
Neutrophils	30±4	23±3	2	
Daudi	34±3	33±2	3	
Raji	18±2	18±2	3	
Molt4	22±3	23±3	3	
Jurkat				

The specific methods of this experiment are detailed in Methods and Materials. In brief, cells from various lines, peripheral blood mononuclear cells and purified granulocytes were incubated first with either Mab32 or mlgG2a and with control myeloma proteins of the mlgG1 subclass. The washed cells were then incubated with FITC anti-mIg, washed again, and analyzed for fluorescence intensity by flow cytometry. Results are expressed as mean fluorescence intensity (MI) in arbitrary units ± SD.

As illustrated in Figure 5, it should be noted that in spite of some overlap in the fluorescence intensity distribution of cells stained with mab 32 and control antibodies, fluorescence intensity plots of all positive cell types indicated a unimodal distribution with mab 32. This suggests that the entire populations of HL60 U937 cells and monocytes, rather than just a major subpopulation, were positive for binding of mab 32.

### Discussion

The development of monoclonal antibodies against the high affinity FcR for IgG of human mononuclear phagocytic cells was a particular challenge because two subclasses of murine IgG, IgG2a and IgG3 are ligands capable of binding with high affinity to this receptor (Anderson C.L. and Abraham, G.N. (1980) *J. Immunol.* 125: 2735-2741; Zubeck, M.D. et al (1985) *J. Immunol.* 135: 1299-1304). Thus, any assay for mabs capable of binding to the receptor would register as positive all antibodies of these two subclasses. Our strategy was designed to deal with this obstacle, however, and we were successful in obtaining monoclonal antibodies of the IgG1 subclass capable of binding this receptor at sites on the outer surface of the plasma membrane distinct from the ligand binding site. The data supporting this conclusion can be summarized briefly for the prototype antibody mab 32:

First, mab 32 is of the IgG1 subclass. This murine IgG subclass has been found incapable of binding to the high affinity FcR. See e.g. Anderson, C. L. and Abraham, G. N. (1980) *J. Immunol.* 125: 2735. Of the seven IgG1 mabs with anti-U937 activity derived from the fusion described above, four of them adsorbed only a 110kDa molecule from lysates of surface radioiodinated U937 cells. Thus, adsorption of the 72kDaFcR is not a general property of IgG1 proteins. (Of the two remaining IgG1 mabs, one adsorbed small amounts of a 72kDa molecule and the other adsorbed both a 72kDa and a 110kDa molecule; these have not yet been further investigated.) Nevertheless, to eliminate the possibility that mab 32 was a variant IgG1 which bound through its Fc region to the FcR, we tested the capacity of Fab' fragments of mab 32 to adsorb the 72kDa FcR and found that binding occurs independently of the Fc portion of the

human peripheral blood monocytes (PBM) were able to kill cRBC in the presence of 32 × Fab anti-CE heteroantibodies, and cytotoxicity was increased by IFN-gamma (Figure 8). A control heteroantibody of Fab 32 × Fab anti-*Streptococcus mutans* did not stimulate control or IFN-gamma treated monocytes to lyse cRBC targets. See Figure 8. 32 × Fab anti-cRBC promoted cell lysis by U937 cells was not inhibited by high levels of blocking IgG1, while cytotoxicity mediated by rabbit anti-cRBC antibody was readily inhibited by IgG1, both with IFN-gamma treated and untreated U937 cells. See Figure 9. Fab 32 × Fab anti-cRBC promoted killing by human PBMs, with or without IFN-gamma treatment, was not inhibited by increasing levels of blocking IgG1. Rabbit anti-PBC antibody promoted killing was quickly inhibited by IgG1 regardless of IFN-gamma induction. See Figure 10.

In an attempt to define the cell surface determinants on human monocytes that act as trigger molecules for cytotoxicity, hybridoma cells (HC) which produced antibody directed to various human monocyte surface molecules were selected for high expression of surface Ig and used directly as target cells. Hybridoma cells expressing surface Ig directed to the high-affinity FcγR were efficiently killed by human monocytes, whereas hybridoma cells expressing surface Ig directed to other molecules present on the monocyte membrane were not lysed. Thus, FcγRI, when appropriately triggered, specifically initiates monocyte-mediated cytotoxicity of tumor target cells. (Graziano and Farger, 1987 J. Immun. 138 945-950).

In previous studies, it has been indicated that IFN-gamma increases both the number of FcγRI molecules per monocyte and the ability of monocytes to mediate ADCC. In the work described here, treatment of monocytes with IFN-gamma did not consistently augment their ability to lyse a hybridoma cell (HC 32.2A

TABLE 3

ADCC OF SCCL CELLS BY HUMAN MONONUCLEAR CELLS				
Heteroantibody	E T			
	ug ml	40:1	60:1	80:1
	% specific cytotoxicity			
SCCL-175 x 32	25	18	24	11
	100	31	37	26

The in vivo efficacy of heteroantibodies composed of mab 32.2 and anti-tumor antibodies may be enhanced by the use of physiological mediators such as IFN-gamma or calcitrol.

The invention relates to human Fc receptor-specific monoclonal antibody, the binding of which to Fc receptor is not blocked by human immunoglobulin G, to a monoclonal antibody which binds, through its antigen binding region, specifically to the high affinity Fc receptor for IgG on human monocytes, the antibody binding site on the receptor being distinct from the ligand binding site for F

consisting of a cancer cell, an infectious agent, an IgE-producing cell or an autoimmune cell, or an antibody-producing cell.

The invention also relates to a target macrophage comprising a macrophage having bound to its surface Fc receptors a heteroantibody comprising: (a) at least one antigen binding region derived from an anti-Fc receptor antibody, the binding of which to human Fc receptor is not blocked by human immunoglobulin G, and (b) at least one antigen binding region specific for a target cell, the bifunctional antibody or heteroantibody being bound to the Fc receptor of the effector cell, the macrophage OPTIONALLY having been treated with IFN-gamma before targeting.

The heteroantibody may comprise: (a) an antibody or antibody binding fragment specific for Fc receptor for IgG on human monocytes, the binding of which to the human Fc receptor is not blocked by human immunoglobulin G, (b) an antibody or antibody binding fragment specific for a target cell.

The invention also relates to targeted effector cells, each comprising: (a) an effector cell expressing receptor for the Fc portion of IgG, (b) at least one antigen binding region derived from an anti-Fc receptor antibody, the binding of which to human Fc receptor is not blocked by human immunoglobulin G, and (c) at least one antigen binding region specific for a tumor cell, the bifunctional antibody or heteroantibody being bound to the Fc receptor of the effector cell for use in diagnosis or therapy, e.g. of cancers, allergies, infectious or immune diseases.

The invention also embraces the use of targeted effector cells for the manufacture of a diagnostic agent or a medicament for therapy, e.g. of cancers, allergies, infectious or immune diseases, said cells each comprising: (a) an effector cell expressing receptor for the Fc portion of IgG, (b) at least one antigen binding region derived from an



2. A method of targeting effector cells (for example human leukocytes (e.g. macrophages), monocytes, IFN-gamma activated natural killer cells and eosinophils) which express Fc receptors comprising the steps of:
  - (a) providing a compound comprising an antigen binding region which binds Fc receptor without being blocked by human IgG; and
  - (b) linking at least one antigen binding region specific for a target cell (for example a cancer cell, an infectious agent or an antibody-producing cell e.g. an IgE producing cell or an autoimmune cell) to the Fc receptors of the effector cells via the antigen binding region of the compound to produce targeted effector cells, the method optionally further comprising the step of activating the effector cells before targeting by a cytokine, for example tumour necrosis factor, lymphotoxin, colony stimulating factor and interleukin-2.
3. The compound of claim 1 or method of claim 2 wherein the antigen binding region comprises or is derived from an antibody (for example a monoclonal antibody e.g. mab 32, mab 22, mab 44, mab 62 and mab 197) or fragment thereof (e.g. a Fab' fragment).
4. The compound or method of any one of claim 1 to 3 wherein the antigen binding region binds to the high affinity Fc receptor for IgG on human monocytes.
5. The compound of any one of claims 1, 3 and 4 for use in:
  - (a) a method of antibody dependent cell mediated cytotoxicity (ADCC), which method comprises the steps of:
    - (i) linking at least one antigen binding region specific for a target cell (for example a cancer cell, an infectious agent or an antibody-producing cell e.g. an IgE producing cell or an autoimmune cell) to the Fc receptor of an effector cell (for example human leukocytes (e.g. macrophages), monocytes, IFN-gamma activated natural killer cells and eosinophils) via the antigen binding region of the compound to produce a targeted effector cell, the linkage being such that it is not disrupted by physiological concentrations of IgG when the targeted effector cells are subsequently;
    - (ii) contacted with the target cell to effect ADCC *in vivo*; or
  - (b) a method of targeting lipid vesicles containing anticancer drugs or monocyte activating factors (e.g. gamma-IFN) to target cells bearing Fc receptor; or
  - (c) a method for "capping" and eliminating Fc receptors on e.g. monocytes; or
  - (d) quantifying the distribution or number of Fc receptors on cells, for example to assay for agents which influence Fc receptor expression (e.g. interferon gamma), to subclassify patients with rheumatological disorders or to radio-image sites of inflammation.
6. The compound of claim 5 wherein the method as defined in claim 6 (a) further comprises the step of activating the effector cells before targeting by use of a cytokine, for example tumour necrosis factor, lymphotoxin, colony stimulating factor and interleukin-2.
7. The method of claims 2 to 4 or compound of claim 5 or 6 wherein the effector cells are obtained from the host to be treated and for example administered as a suspension of cells in a physiologically acceptable solution in an amount sufficient to obtain localization at the target cell and to effect ADCC.
8. Targeted effector cells producible by the method of any one of claims 2 to 4.
9. An immunoassay for FcR1 receptor levels or for a substance which influences FcR1 receptor levels comprising the steps of:
  - (a) providing a compound comprising an antigen binding region which binds Fc receptor without being blocked by human IgG;
  - (b) contacting a sample to be tested with the compound of step (a); and
  - (c) measuring the amount of compound bound to the sample.
10. An immunoassay according to claim 9 for quantifying interferon-gamma in a sample, wherein in step (b) the sample to be tested is first contacted with human cells that increase FcR1 expression upon stimulation with interferon-gamma such that step (c) measures the FcR1 level of the cells as an indication of the amount of interferon gamma in the sample.




Fig 1

Lane	Preclearing Adsorbant	Final Adsorbant	Band Density	OD/Exposure
1	migG1	migG2a	310	...
2	migG1	32	217	...
3	migG2a	32	23	89
4	32	migG2a	85	73
5	32	32	42	81
6	migG2a	migG2a	20	93

Fig 2




Fig 3




Fig 5






Figure 1b


## DIRECT BINDING OF FITC MAb TO U-937 CELLS




# ADCC OF CRBC BY IFN- $\gamma$ -TREATED U937 CELLS CYTOTOXICITY MEDIATED BY HETEROANTIBODY 32 X Fab anti-cRBC




ADCC MEDIATED BY HETEROANTIBODY  
Fab 32 X Fab anti-cRBC




# HUMAN MONOCYTE ADCC MEDIATED BY HETEROANTIBODY 32 X Fab anti-cRBC



77-77  
HETEROANTIBODY ADCC OF cRBC BY  
IFN- $\gamma$ -TREATED U937 CELLS











Europäisches Patentamt  
European Patent Office  
Office européen des brevets



Publication number:

**0 629 703 A3**

## EUROPEAN PATENT APPLICATION

Application number: **94202572.7**

Int. Cl.<sup>6</sup> **C12P 21/00, A61K 39 395,  
G01N 33 577, G01N 33 68**

Date of filing: **07.07.87**

Priority: **07.07.86 US 882181  
01.07.87 US 69412**

Date of publication of application:  
**21.12.94 Bulletin 94/51**

Publication number of the earlier application in  
accordance with Art.76 EPC: **0 255 249**

Designated Contracting States:  
**AT BE CH DE ES FR GB GR IT LI LU NL SE**

Date of deferred publication of the search report.  
**22.03.95 Bulletin 95/12**

Applicant: **MEDAREX, INC.  
12 Commerce Drive  
West Lebanon, NH 03784 (US)**

Inventor: **Fanger, Michael W.  
West View Lane Box 421  
Lebanon,  
New Hampshire 03766 (US)**  
Inventor: **Guyre, Paul M.  
Pinneo Hill Road  
Hanover,  
New Hampshire 03755 (US)**  
Inventor: **Anderson, Clark L.  
406 West Sixth Avenue  
Columbus,  
Ohio 43201 (US)**

Representative: **Harvey, David Gareth et al  
Graham Watt & Co.  
Riverhead  
Sevenoaks  
Kent TN13 2BN (GB)**

**Monoclonal antibodies to Fc receptors for immunoglobulin G on human mono-nuclear phagocytes, bifunctional antibodies, target specific effector cells, targeted macrophages, and immunoassays.**

A human Fc receptor-specific monoclonal antibody is disclosed together with its mode of preparation. Binding of the antibody to Fc receptor is not blocked by human immunoglobulin G. The antibody binds to the high affinity Fc receptor for IgG on human monocytes at a receptor binding site distinct from the ligand binding site for Fc.

A bifunctional antibody or a heteroantibody has an antigen binding region derived from an anti-Fc receptor antibody and an antigen binding region specific for a target epitope or cell; such antibody may target a macrophage when it is bound to surface Fc receptors of the macrophage.

A target-specific effector cell expresses receptor for the Fc portion of IgG, has one antigen binding

another specific for a target cell, and the aforesaid bifunctional or hetero-antibody is bound to the Fc receptor of the effector cell; such effector cell can be used in the therapy of cancers, allergies, infectious and autoimmune diseases, and in immunoassays.

**EP 0 629 703 A3**



European Patent  
Office

## EUROPEAN SEARCH REPORT

Application Number  
EP 94 20 2572

DOCUMENTS CONSIDERED TO BE RELEVANT					
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.4)		
D,X	JOURNAL OF EXPERIMENTAL MEDICINE, vol.160, December 1984, NEW YORK US pages 1686 - 1701 B. KARPOVSKY ET AL. * whole document, especially page 1698, last paragraph *	1,2,4,5, 8	C12P21/00 A61K39/395 G01N33/577 G01N33/68		
X	FEDERATION PROCEEDINGS, vol.45, no.2, February 1986, WASHINGTON US page 714 C.L. ANDERSON ET AL. * Abstract *	1,3,4			
D,X	JOURNAL OF IMMUNOLOGY, vol.134, no.1, January 1985, BALTIMORE US pages 465 - 470 C.L. ANDERSON ET AL. * page 469, column 2, line 52 - line 60 *	1,4			
X	CHEMICAL ABSTRACTS, vol. 103, no. 11, 16 September 1985, Columbus, Ohio, US; abstract no. 86103r, E. RECTOR ET AL. page 462 ;column 1 ; & IMMUNOLOGY, vol.55, no.3, 1985 pages 481 - 488	1	<table border="1"><thead><tr><th>TECHNICAL FIELDS SEARCHED (Int.Cl.4)</th></tr></thead><tbody><tr><td>C07K G01N</td></tr></tbody></table>	TECHNICAL FIELDS SEARCHED (Int.Cl.4)	C07K G01N
TECHNICAL FIELDS SEARCHED (Int.Cl.4)					
C07K G01N					
D,Y	THE JOURNAL OF CLINICAL INVESTIGATION, vol.72, no.1, July 1983, NEW YORK US pages 393 - 397 P.M. GUYRE ET AL. * the whole document *	10			
Y	GB-A-2 048 472 (YEDA RESEARCH AND DEVELOPMENT COMPANY LIMITED) * the whole document *	10			
-/--					
The present search report has been drawn up for all claims					
Place of search		Date of completion of the search	Examiner		
BERLIN		23 December 1994	De Kok, A		
<table><tr><td><b>CATEGORY OF CITED DOCUMENTS</b> X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document</td><td><b>Legend</b> I : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons A : member of the same patent family, corresponding document</td></tr></table>				<b>CATEGORY OF CITED DOCUMENTS</b> X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document	<b>Legend</b> I : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons A : member of the same patent family, corresponding document
<b>CATEGORY OF CITED DOCUMENTS</b> X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document	<b>Legend</b> I : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons A : member of the same patent family, corresponding document				



European Patent  
Office

## EUROPEAN SEARCH REPORT

Application Number  
EP 94 20 2572

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.4)
A	I.M. ROITT ET AL. 'immunology' 1985 , CHURCHILL LIVINGSTONE , LONDON GB * pp. 2.4, 5.6-5.7, 11.6-11.7, 16.5-16.6, 18.2-18.7, 19.9, 20.1-20.2 *	1-10	
P,X	THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol.261, no.27, 25 September 1986, BALTIMORE US pages 12856 - 12864 C.L. ANDERSON ET AL. * the whole document *	1,3,4,9, 10	
P,X	THE JOURNAL OF IMMUNOLOGY, vol.137, no.11, 1 December 1986, BALTIMORE US pages 3378 - 3382 L. SHEN ET AL. * the whole document *	1-10	
			TECHNICAL FIELDS SEARCHED (Int.Cl.4)
The present search report has been drawn up for all claims			
Place of search BERLIN		Date of completion of the search 23 December 1994	Examiner De Kok, A
<b>CATEGORY OF CITED DOCUMENTS</b>			
<p>X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document</p> <p>I : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons A : member of the same patent family, corresponding document</p>			

